Articles

A rare genetic mutation protects against Alzheimer’s disease

Data from a highly resilient individual guided researchers to new potential therapeutic targets.  
Written byHannah Thomasy, PhD
| 4 min read
A man in a tan sweater works on a puzzle in the shape of a human head.

Rates of Alzheimer’s disease are rising, and treatment options remain limited.

credit: istock/LightFieldStudios

Globally, an estimated 55 million people suffer from Alzheimer's disease and other forms of dementia, a number that is expected to rise steeply in the coming years (1). For decades, scientists have studied genetic contributions to risk and resilience in the context of this disease, hoping to shed light on disease processes and identify new molecular targets.

In 2019, researchers discovered a genetic quirk known as the APOE3 Christchurch mutation that seemed to protect against autosomal dominant Alzheimer's disease (ADAD), an early-onset, genetically determined form of the disease (2). Now, researchers have identified a second protective mutation: a gain-of-function mutation in RELN, the gene encoding the protein Reelin (3). Reelin plays many important roles in brain structure and function, including processes like neuronal migration and synaptic plasticity. The newly discovered RELN gene variant, which researchers named RELN-COLBOS, provides new insight into signalling pathways that may protect patients from this devastating disease.

“This discovery would not have happened without the generosity of this patient,” said coauthor Joseph Arboleda-Velasquez, who studies neurodegenerative diseases of the brain and retina at Harvard Medical School. “It’s just amazing to see how one person committing to research can make such a huge difference.”

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

  • Hannah Thomasy

    Hannah joined Drug Discovery News as an assistant editor in 2022. She earned her PhD in neuroscience from the University of Washington in 2017 and completed the Dalla Lana Fellowship in Global Journalism in 2020. Her work has appeared in The New York Times, Undark, and New Scientist. She enjoys playing soccer and hiking and hopes to be a contestant on The Great Canadian Baking Show one day. 

    View Full Profile

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D molecular visualization of a protein structure, rendered in a ribbon diagram style.
A comparative structural analysis of MC4R complexes reveals how agonist binding influences receptor conformation, ligand interactions, and complex stability.
Gloved hand holding a multiwell cell culture plate under a fluorescence microscope for spheroid analysis.
Using confocal live-cell imaging to characterize immune-mediated cytotoxicity over time.
Fluorescence microscopy image of cells displaying green and red fluorescent signals.
Using confocal live-cell imaging to assess treatment effects in spheroids, organoids, and co-cultures.